1. BASKET-SAVAGE
Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were recommended to receive a glycoprotein IIb/IIIa inhibitor and a distal protection device (FilterWire) during PCI.
Results
(p < 0.001)
Cardiac death, nonfatal MI, or TVR at 12 months: 2.3% of the DES group versus 17.9% of the BMS group (p < 0.001)
Stent thrombosis: 0 versus 4.8% (p = 0.09); respectively, for DES versus BMS
Major bleeding: 2.3% versus 2.4% (p = 0.91); respectively, for DES versus BMS
17.9 %
2.3
Conclusions
Among patients with a SVG lesion, the use of a DES was associated with a reduction in major adverse events compared with a BMS
Risk of stent thrombosis and major bleeding was the same between treatment groups
DES
BMS
Presented by Dr. Raban Jeger at ESC 2016